Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Microbot Medical Inc.NASDAQ: MBOT
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.
Context
- Income tax expense increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Income Tax Expense vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
- Income tax expense amounts to 0.0% of revenue for MBOT, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.85M USD | +480.1% | +383.6% | — | |
| LTM Mar 2026 | $12.61M USD | +127.4% | — | 4.2% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | -$9K USD | -128.1% | -32.6% | 0.0% | |
| Peer median (excluding MBOT) | — | +127.4% | +175.5% | 0.0% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 106K | 91K | 0 |
| Gross Profit | 0 | 0 | (106K) | (91K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.15M | 7.74M | 5.72M | 6.63M | 6.28M |
| Selling, General & Admin | 5.41M | 5.58M | 4.13M | 5M | 8.25M |
| Operating Expenses | 11.36M | 13.28M | 9.75M | 11.53M | 14.74M |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| EBITDA | (11.24M) | (13.34M) | (10.63M) | (11.35M) | (13.1M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (11.36M) | (13.28M) | (9.86M) | (11.63M) | (14.74M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 44K | 54K | 228K | 182K | 1.29M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 44K | 113K | (885K) | 182K | 1.6M |
| Income Before Tax | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) |
| EPS (Diluted) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) |
| Weighted Avg Shares | 7.11M | 7.26M | 10.2M | 15.65M | 45.79M |
| Weighted Avg Shares (Diluted) | 7.11M | 7.26M | 10.2M | 15.65M | 45.79M |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.